<DOC>
	<DOCNO>NCT00890552</DOCNO>
	<brief_summary>This open-label trial evaluate use lenalidomide ; melphalan ; dexamethasone ( MDR ) treat newly diagnose relapse AL amyloidosis , course nine 28-day cycle .</brief_summary>
	<brief_title>A Pilot Study Lenalidomide , Melphalan Dexamethasone AL Amyloidosis</brief_title>
	<detailed_description>The study evaluate 3-drug combination lenalidomide ; melphalan ; dexamethasone ( MDR ) absence disease progression toxicity , patient complete nine 28-day cycle MDR therapy , option continue treatment lenalidomide single-agent . Patients receive nine cycle treatment , option continue lenalidomide single agent respond treatment .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>INCLUSION CRITERIA Newly diagnose relapse AL amyloidosis Biopsyproven amyloidosis evidence underlie plasma cell dyscrasia abnormal clonal dominance plasma cell bone marrow detection monoclonal gammopathy immunofixation electrophoresis serum and/or urine abnormal serum free light chain ratio , AL fibrils see biopsy ) Measurable disease define abnormal serumfree light chain monoclonal protein immunofixation proteinuria ≥ 0.5 g/day , cardiac involvement interventricular septal thickness ≥ 15 mm hepatomegaly absence congestive heart failure elevate alkaline phosphatase Age ≥ 18 year time signing informed consent form . All previous cancer therapy must discontinue least 4 week prior treatment study ECOG performance status ≤ 3 study entry Laboratory test result : Absolute neutrophil count ≥ 1.0 x 10e9 / L Platelet count ≥ 75 x 10e9 / L Creatinine clearance ≥ 15 mL/ minute Total bilirubin ≤ 2fold upper limit normal Diseasefree prior malignancy ( exclude multiple myeloma ) ≥ 3 year exception : currently treat basal cell squamous cell carcinoma skin carcinoma `` situ '' cervix breast . Females childbearing potential ( FCBP ) must negative serum urine pregnancy test Females childbearing potential must either : commit continue abstinence heterosexual intercourse acceptable method birth control agree ongoing pregnancy test Men must agree use latex condom sexual contact FCBP even successful vasectomy All study participant must register mandatory RevAssist program , able comply requirement Able take aspirin ( 81 mg ) daily • Understand voluntarily sign informed consent form Able adhere study visit schedule protocol requirement EXCLUSION CRITERIA Any serious medical condition would prevent subject signing informed consent form Pregnant breastfeeding female Use experimental drug therapy within 28 day baseline Known hypersensitivity thalidomide Erythema nodosum characterize desquamate rash take thalidomide similar drug Any prior use lenalidomide Concurrent use anticancer agent treatment Known positivity human immunodeficiency virus HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>